文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

缺氧诱导的FAM99A和FAM99B抑制促进肝细胞癌的发生和葡萄糖代谢重编程。

Hypoxia-Induced Suppression of FAM99A and FAM99B Contributes to the Development and Glucose Metabolic Reprogramming of Hepatocellular Carcinoma.

作者信息

Song Cang-Sang, Wang Guo-Hui, Mao Pan-Pan, Zhang Han-Shu, Liu Lu, Ma Xue-Jiao, Li Xing-de, Zhang Yang

机构信息

Department of Pharmacy, The First People's Hospital of Kunming City & Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

Department of Pharmacy, The Third People's Hospital of Yunnan Province, Kunming, Yunnan, China.

出版信息

FASEB J. 2025 Jul 31;39(14):e70869. doi: 10.1096/fj.202501058R.


DOI:10.1096/fj.202501058R
PMID:40693878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12282501/
Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive and highly malignant cancer. Glucose metabolic reprogramming provides sufficient ATP to support HCC's rapid proliferation and invasion. Consequently, this study intends to investigate the effects of FAM99A and FAM99B on glucose metabolic reprogramming, and provide new insights for HCC treatment. Changes in malignant phenotypes and glycolysis-related indices of HCC cells (HCCLM3 and HEPG2) were assessed after exogenous regulation of FAM99A and FAM99B under hypoxic conditions. Oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and glycolytic proton efflux rate (glycoPER) were measured using the Seahorse XF Glycolysis Rate Assay Kit (103344-100, Agilent). HCCLM3 cells were subjected to transcriptome and smallRNA sequencing to identify differentially expressed genes (DEGs) and miRNAs (DE-miRNAs) associated with FAM99A and FAM99B. Under hypoxic conditions, the expression of FAM99A and FAM99B was significantly downregulated in HCC cells. Overexpression of FAM99A or FAM99B significantly inhibited HCC cell proliferation, wound healing, and invasion. Moreover, they effectively decreased intracellular glucose, extracellular lactate, ATP, glycolysis-related enzymes, ECAR, and glycoPER, and increased pH, extracellular glucose, and mitoOCR/glycoPER. A total of 31 DEGs and 15 DE-miRNAs were present in HCCLM3 cells overexpressing FAM99A, and 375 DEGs and 68 DE-miRNAs were identified in HCCLM3 cells overexpressing FAM99B. These DEGs and DE-miRNA targets were involved in cell cycle, apoptosis, metastasis, extracellular matrix remodeling, and metabolic reprogramming. The FAM99B-associated ceRNA network contained one DE-miRNA and 10 DEGs, and their expression differences were consistent with the sequencing results. Hypoxia-induced suppression of FAM99A and FAM99B facilitates proliferation, metastasis, and glucose metabolic reprogramming of HCC.

摘要

肝细胞癌(HCC)是一种侵袭性极强且恶性程度很高的癌症。葡萄糖代谢重编程可提供足够的三磷酸腺苷(ATP)来支持肝癌细胞的快速增殖和侵袭。因此,本研究旨在探究FAM99A和FAM99B对葡萄糖代谢重编程的影响,为肝癌治疗提供新的见解。在缺氧条件下对外源性FAM99A和FAM99B进行调控后,评估肝癌细胞(HCCLM3和HEPG2)恶性表型和糖酵解相关指标的变化。使用Seahorse XF糖酵解速率检测试剂盒(103344 - 100,安捷伦公司)测量氧消耗率(OCR)、细胞外酸化率(ECAR)和糖酵解质子外流率(glycoPER)。对HCCLM3细胞进行转录组和小RNA测序,以鉴定与FAM99A和FAM99B相关的差异表达基因(DEG)和微小RNA(DE - miRNA)。在缺氧条件下,肝癌细胞中FAM99A和FAM99B的表达显著下调。FAM99A或FAM99B的过表达显著抑制肝癌细胞的增殖、伤口愈合和侵袭。此外,它们有效降低了细胞内葡萄糖、细胞外乳酸、ATP、糖酵解相关酶、ECAR和glycoPER,并提高了pH值、细胞外葡萄糖和线粒体氧消耗率/糖酵解质子外流率(mitoOCR/glycoPER)。在过表达FAM99A的HCCLM3细胞中共有31个DEG和15个DE - miRNA,在过表达FAM99B的HCCLM3细胞中鉴定出375个DEG和68个DE - miRNA。这些DEG和DE - miRNA靶标参与细胞周期、凋亡、转移、细胞外基质重塑和代谢重编程。与FAM99B相关的竞争性内源RNA(ceRNA)网络包含1个DE - miRNA和10个DEG,它们的表达差异与测序结果一致。缺氧诱导的FAM99A和FAM99B抑制促进了肝癌的增殖、转移和葡萄糖代谢重编程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8909538391ab/FSB2-39-e70869-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/246bee623604/FSB2-39-e70869-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/084e45018f28/FSB2-39-e70869-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8589952a3c1e/FSB2-39-e70869-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/e61d06668bd9/FSB2-39-e70869-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/af1d320c3df5/FSB2-39-e70869-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/1d4315ec6d7e/FSB2-39-e70869-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/5d6ceac4daa4/FSB2-39-e70869-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8d90798cdc66/FSB2-39-e70869-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8909538391ab/FSB2-39-e70869-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/246bee623604/FSB2-39-e70869-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/084e45018f28/FSB2-39-e70869-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8589952a3c1e/FSB2-39-e70869-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/e61d06668bd9/FSB2-39-e70869-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/af1d320c3df5/FSB2-39-e70869-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/1d4315ec6d7e/FSB2-39-e70869-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/5d6ceac4daa4/FSB2-39-e70869-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8d90798cdc66/FSB2-39-e70869-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b75e/12282501/8909538391ab/FSB2-39-e70869-g010.jpg

相似文献

[1]
Hypoxia-Induced Suppression of FAM99A and FAM99B Contributes to the Development and Glucose Metabolic Reprogramming of Hepatocellular Carcinoma.

FASEB J. 2025-7-31

[2]
A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion.

J Cancer Res Clin Oncol. 2019-6-26

[3]
mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.

Theranostics. 2022

[4]
High glucose facilitates hepatocellular carcinoma cell proliferation and invasion via WTAP-mediated HK2 mRNA stability.

Mol Cell Biochem. 2025-3-3

[5]
The comprehensive roles of lncRNA FAM99A/FAM99B in hepatocellular carcinoma: Expressions, regulatory mechanisms and functional pathway analysis.

Life Sci. 2024-7-15

[6]
Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.

J Exp Clin Cancer Res. 2025-7-15

[7]
Potential regulatory mechanism of overexpression of phosphatidylinositol glycan anchor biosynthesis class U on the glycolytic pathway in hepatocellular carcinoma.

Gene. 2025-6-3

[8]
Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.

J Cancer Res Clin Oncol. 2018-2

[9]
MTFR2 accelerates hepatocellular carcinoma mediated by metabolic reprogramming via the Akt signaling pathway.

Cell Signal. 2024-11

[10]
MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming.

Br J Cancer. 2019-12-10

本文引用的文献

[1]
HBx downregulated decorin and decorin-derived peptides inhibit the proliferation and tumorigenicity of hepatocellular carcinoma cells.

FASEB J. 2023-4

[2]
In silico analysis of the association between long non-coding RNA family with sequence similarity 99 member A (FAM99A) and hepatic cancer.

IET Syst Biol. 2023-4

[3]
A metabolism-related gene signature for predicting the prognosis in thyroid carcinoma.

Front Genet. 2023-1-4

[4]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[5]
Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma.

BMC Cancer. 2022-10-26

[6]
Cross talk between glucose metabolism and immunosuppression in IFN-γ-primed mesenchymal stem cells.

Life Sci Alliance. 2022-9-9

[7]
MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma.

Cancer Res. 2022-11-15

[8]
Metabolic tricks of cancer cells.

Biochim Biophys Acta Rev Cancer. 2022-5

[9]
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.

Acta Pharm Sin B. 2022-2

[10]
Cancer statistics in China and United States, 2022: profiles, trends, and determinants.

Chin Med J (Engl). 2022-2-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索